23Oct, 18MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D InfectionsMYR Pharma today announced that US Food and Drug Administration (FDA) has granted the Breakthrough Therapy designation...
15Mar, 12Press Release, Moscow, March 15th, 2012Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program Co-Invests with Germany’s Public/Private...
07Mar, 19MYR Pharmaceuticals Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D InfectionsMYR Pharmaceuticals announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has...
23Mar, 16Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV InfectionHepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label,...
13Apr, 19ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression bILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with...
